MedTrace Logo

Effects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's Disease

NCT03173781 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2018-06-25

No results posted yet for this study

Summary

The purpose of this study is to determine if droxidopa reduces fall risk by improving gait speed, kyphosis, and functional reach in individuals with Parkinson's disease.

Conditions

Interventions

DRUG

droxidopa

medication

DRUG

Placebo

medication

Sponsors & Collaborators

  • H. Lundbeck A/S

    collaborator INDUSTRY

  • Colorado Springs Neurological Associates

    lead OTHER

Principal Investigators

  • Christen Kutz, PhD, PA-C · Colorado Springs Neurological Associates

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2017-10-31
Completion
2017-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03173781 on ClinicalTrials.gov